A detailed history of Erste Asset Management Gmb H transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Erste Asset Management Gmb H holds 42,000 shares of APLS stock, worth $1.22 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
42,000
Holding current value
$1.22 Million
% of portfolio
0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$28.84 - $41.15 $1.21 Million - $1.73 Million
42,000 New
42,000 $1.24 Billion
Q4 2023

Nov 26, 2024

BUY
$37.14 - $64.82 $668,520 - $1.17 Million
18,000 Added 75.0%
42,000 $2.64 Billion
Q3 2023

Nov 26, 2024

SELL
$23.65 - $89.22 $307,450 - $1.16 Million
-13,000 Reduced 35.14%
24,000 $952 Million
Q2 2023

Nov 26, 2024

BUY
$76.68 - $93.31 $920,160 - $1.12 Million
12,000 Added 30.26%
51,650 $4.6 Billion
Q1 2023

Nov 26, 2024

BUY
$46.59 - $66.96 $123,463 - $177,443
2,650 Added 7.16%
39,650 $2.62 Billion
Q3 2022

Nov 26, 2024

SELL
$44.76 - $69.66 $223,800 - $348,300
-5,000 Reduced 11.9%
37,000 $2.42 Billion
Q2 2022

Nov 26, 2024

SELL
$35.07 - $59.21 $175,350 - $296,050
-5,000 Reduced 11.9%
37,000 $1.67 Billion
Q1 2022

Nov 22, 2024

BUY
$35.46 - $54.12 $709,200 - $1.08 Million
20,000 Added 117.65%
37,000 $1.83 Billion
Q4 2021

Nov 22, 2024

SELL
$30.74 - $49.16 $153,700 - $245,799
-5,000 Reduced 11.9%
37,000 $1.75 Billion
Q3 2021

Nov 22, 2024

SELL
$31.4 - $69.84 $530,660 - $1.18 Million
-16,900 Reduced 49.85%
17,000 $577 Million
Q4 2020

Nov 22, 2024

SELL
$30.79 - $57.2 $249,399 - $463,320
-8,100 Reduced 19.29%
33,900 $1.86 Billion

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.19B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Erste Asset Management Gmb H Portfolio

Follow Erste Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Erste Asset Management Gmb H with notifications on news.